Sensato Investors LLC Invests $3.05 Million in Novartis AG (NVS) Stock
Sensato Investors LLC purchased a new stake in shares of Novartis AG (NYSE:NVS) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 36,300 shares of the company’s stock, valued at approximately $3,048,000.
A number of other large investors also recently added to or reduced their stakes in NVS. Capital Bank & Trust Co increased its stake in Novartis by 5.5% during the third quarter. Capital Bank & Trust Co now owns 138,207 shares of the company’s stock worth $11,865,000 after acquiring an additional 7,201 shares during the last quarter. Atlantic Trust Group LLC grew its stake in Novartis by 54.2% in the third quarter. Atlantic Trust Group LLC now owns 72,427 shares of the company’s stock worth $6,218,000 after purchasing an additional 25,452 shares in the last quarter. Rothschild Investment Corp IL grew its stake in Novartis by 26.9% in the fourth quarter. Rothschild Investment Corp IL now owns 26,200 shares of the company’s stock worth $2,200,000 after purchasing an additional 5,550 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new position in Novartis in the third quarter worth approximately $1,245,000. Finally, Cedar Hill Associates LLC bought a new position in Novartis in the third quarter worth approximately $248,000. 10.80% of the stock is owned by institutional investors and hedge funds.
Shares of Novartis AG (NVS) opened at $82.26 on Wednesday. The company has a current ratio of 1.21, a quick ratio of 0.91 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $192,140.30, a price-to-earnings ratio of 25.31, a price-to-earnings-growth ratio of 1.93 and a beta of 0.78. Novartis AG has a twelve month low of $72.67 and a twelve month high of $94.19.
A number of analysts have weighed in on the company. Nord/LB restated a “neutral” rating on shares of Novartis in a report on Tuesday, January 2nd. Bank of America lowered Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Zacks Investment Research lowered Novartis from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. UBS Group restated a “neutral” rating on shares of Novartis in a report on Monday, January 15th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis in a report on Thursday, January 18th. Four analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company’s stock. Novartis presently has a consensus rating of “Hold” and a consensus price target of $87.51.
TRADEMARK VIOLATION NOTICE: This story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2018/03/14/sensato-investors-llc-invests-3-05-million-in-novartis-ag-nvs-stock.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.